Literature DB >> 24435325

Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.

Roza Badr Eslam1, Florian Posch, Irene M Lang, Thomas Gremmel, Beate Eichelberger, Cihan Ay, Simon Panzer.   

Abstract

We studied the association of thrombin generation potential with platelet protease activated receptor (PAR)-1 regulation and platelet activation in 52 stable coronary artery disease patients on continuous therapy with aspirin and clopidogrel (n = 42) or prasugrel (n = 10). Compared to controls, peak thrombin generation potential was elevated in only 11 patients (p > 0.05), while F1.2 was elevated in 26 patients (p < 0.0001). PAR-1 and thrombin inducible P-selectin expression were significantly elevated in patients compared to controls (p < 0.001). There were no significant correlations between levels of thrombin generation potential or F1.2 and PAR-1 regulation. However, there was a significant inverse correlation between levels of peak thrombin generation potential and in vitro thrombin-inducible expression of P-selectin (p = 0.002), suggesting in vivo depletion of platelet alpha granules due to ongoing platelet activation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24435325     DOI: 10.1007/s12265-013-9531-7

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  30 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

3.  Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.

Authors:  Soochong Kim; Carolyn Foster; Anna Lecchi; Todd M Quinton; Dina M Prosser; Jianguo Jin; Marco Cattaneo; Satya P Kunapuli
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

Review 4.  Protease-activated receptors in cardiovascular diseases.

Authors:  Andrew J Leger; Lidija Covic; Athan Kuliopulos
Journal:  Circulation       Date:  2006-09-05       Impact factor: 29.690

5.  Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib.

Authors:  G Soslau; R Class; D A Morgan; C Foster; S T Lord; P Marchese; Z M Ruggeri
Journal:  J Biol Chem       Date:  2001-03-30       Impact factor: 5.157

Review 6.  Thrombin generation testing in routine clinical practice: are we there yet?

Authors:  J J van Veen; A Gatt; M Makris
Journal:  Br J Haematol       Date:  2008-06-28       Impact factor: 6.998

7.  Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.

Authors:  Thomas Gremmel; Christoph W Kopp; Daniela Seidinger; Renate Koppensteiner; Sabine Steiner; Simon Panzer
Journal:  Eur J Clin Invest       Date:  2013-04-24       Impact factor: 4.686

8.  Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test.

Authors:  Josune Orbe; Maite Zudaire; Rosario Serrano; Isabel Coma-Canella; Sara Martínez de Sizarrondo; Jose A Rodríguez; Jose A Páramo
Journal:  Thromb Haemost       Date:  2008-02       Impact factor: 5.249

9.  Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alpha-thrombin.

Authors:  Frederick A Ofosu; Lori Dewar; Sharon J Craven; Yingqi Song; Aisha Cedrone; John Freedman; John W Fenton
Journal:  J Biol Chem       Date:  2008-08-05       Impact factor: 5.157

Review 10.  Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection.

Authors:  M Cattaneo
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

View more
  2 in total

Review 1.  Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine.

Authors:  Emanuele Barbato; Paul J Barton; Jozef Bartunek; Sally Huber; Borja Ibanez; Daniel P Judge; Enrique Lara-Pezzi; Craig M Stolen; Angela Taylor; Jennifer L Hall
Journal:  J Cardiovasc Transl Res       Date:  2015-10-09       Impact factor: 4.132

2.  Clopidogrel Therapy in Patients with Cardiovascular Disease Undergoing Transurethral Resection of the Prostate: A Step Towards Individualization.

Authors:  Petros Tzimas; Maria Tsoumani; Dimitrios Giannakis; Kallirroi Kalantzi; Anastasios Petrou; Vasileios Chantzichristos; Nikolaos Sofikitis; Georgios Papadopoulos; Haralampos Milionis; Alexandros Tselepis
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.